The relevance of T 3 in the management of hypothyroidism.

Levothyroxine monotherapy has been the standard of care for treatment of hypothyroidism for more than 40 years. However, patients treated with levothyroxine have relatively lower serum tri-iodothyronine (T ₃ ) concentrations than the general population, and symptoms of hypothyroidism persist for some patients despite normalisation of thyroid-stimulating hormone (TSH) concentrations. The understanding that maintenance of normal T ₃ concentrations is the priority for the thyroid axis has redirected the clinical focus to serum T ₃ concentrations in patients with hypothyroidism. This Personal View explores whether it is currently feasible to identify patients who could be considered for liothyronine supplementation in combination with levothyroxine. Genetic profiling stands out as a potential future tool to identify patients who do not respond well to levothyroxine due to suboptimal peripheral thyroxine (T ₄ ) activation. Moreover, new slow-release liothyronine preparations are being developed to be trialled in these symptomatic patients, in an attempt to restore T ₃ concentrations and provide conclusive results for the use of T ₄ plus T ₃ combination therapy.
Competing Interests: Declaration of interests ACB is a consultant for AbbVie (makers of Synthroid), Allergan (makers of Armor Thyroid), and Synthonics, Sention Therapeutics, and Thyron (makers of non-clinically available products). All other authors declare no competing interests.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)